Evidence map›Paper›PMID 42210357›Full record

ReviewBiomedical engineering online2026

Plant-mediated green nanoparticles: combining nanometal and biometabolite potential for Alzheimer's treatment.

Farahnaz Behzad, Foad Rahmanpour Leili, MohammadJavad Ebrahimi, Maral Moafi, Pourya Bagherian Kenari, Ali Alizadeh, Soheila Adeli, Masood Khosravani, Mohammad Amin Jadidi Kouhbanani, Javad Fahanik-Babaei

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Biomedical engineering online, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Farahnaz Behzad *Department of Medical Nanotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Foad Rahmanpour Leili *MD, Faculty of Medicine, Department of Neurology, Tonekabon Branch, Islamic Azad University, Tonekabon, Iran.
MohammadJavad EbrahimiCell Biology and Anatomical Sciences, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Maral MoafiCell Biology and Anatomical Sciences, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Pourya Bagherian KenariSchool of Medicine, Babol University of Medical Sciences, Babol, Iran.
Ali AlizadehDepartment of Medical Physics and Biomedical Engineering, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Soheila AdeliElectrophysiology Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran.
Masood KhosravaniDepartment of Medical Nanotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Mohammad Amin Jadidi KouhbananiDepartment of Medical Nanotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran. aminjadidi1993@gmail.com.
Javad Fahanik-BabaeiElectrophysiology Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran. j-fbabaei@farabi.tums.ac.ir.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alzheimer's disease (AD) can cause cognitive and memory dysfunction due to insufficient acetylcholine (ACh). In principle, acetylcholinesterase (AChE) hydrolyzes ACh into acetic acid and choline, rendering the latter inactive. Acetylcholinesterase inhibitors (AChEI) are currently the main treatment strategy used to increase ACh availability and decrease the effects of cholinergic loss. The FDA has currently approved donepezil, rivastigmine, and galantamine (GAL) as AchEI drugs to treat AD. Among these drugs, only the alkaloid galantamine is found naturally among the AChEIs. The synergistic effect of plant metabolites and metal nanoparticles (MNPs) presents a promising avenue for AD treatment. Green synthesis approach leverages the unique properties of MNPs combined with the therapeutic potential of plant-derived compounds. In the present review, recent developments in nanotechnology, including the green synthesis of MNPs, have been discussed in relation to the treatment of AD. Given the recent advancements, we hope that the combination of nanotechnology and medicinal plants will eventually result in the development of highly successful strategies for the treatment of AD.

Indexed as

Alzheimer DiseaseGreen Chemistry TechnologyMetal NanoparticlesPlantsAnimalsCholinesterase InhibitorsHumansNanotechnologyCholinesterase InhibitorsAcetylcholinesterase inhibitorsAlzheimer’s diseaseGreen synthesisMetal nanoparticlesPlant metabolites

Identifiers

PMID42210357
PMCPMC13491619

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.